Abstract
1Centre for Heart Lung Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada. 2Division of Critical Care Medicine, Department of Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada. Dr. Russell received funding from Ferring Pharmaceutical, Asahi Kesai Pharmaceuticals of America, and Cytoval; disclosed off-label product use (Selepressin); and received other support from Grifols La Jolla Pharmaceuticals Cubist (now owned by Merck) Leading Biosciences. He disclosed other support (he reports patents owned by the University of British Columbia [UBC] that are related to PCSK9 inhibitor[s] and sepsis and related to the use of vasopressin in septic shock. He is an inventor on these patents. He is a founder, Director, and shareholder in Cyon Therapeutics [developing a sepsis therapy]. He has share options in Leading Biosciences. He is a shareholder in Molecular You. He reports having received grant support from Ferring Pharmaceuticals that was provided to and administered by UBC). Dr. Genga is sponsored by Science Without Borders Scholarship Program. For information regarding this article, E-mail: [email protected]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
